REG - Oxford BioDynamics - Results of Annual General Meeting

Oxford BiodynamicsAnnouncement

20/03/2020 13:40

RNS Number : 0500H
  
Oxford BioDynamics PLC
  
20 March 2020
  
 

20 March 2020
 
Oxford BioDynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the "Group")
 
Results of Annual General Meeting
 
Oxford BioDynamics Plc (AIM: OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory 3D genome architecture, using its liquid biopsy platform EpiSwitch™, is pleased to announce that all resolutions as set out in the Notice of Annual General Meeting dated 23 January 2020 were duly passed today by the shareholders of the Company.
 
-ENDS-
 
For further details please contact:
 



Oxford BioDynamics Plc 
Christian Hoyer Millar, CEO 
Paul Stockdale, CFO
 


+44 (0)1865 518910




Shore Capital
Nominated Advisor and Broker
Edward Mansfield 
Stephane Auton
John More


+44 (0)20 7408 4090 




FTI Consulting 
Financial Public Relations Adviser
Natalie Garland-Collins


+44 (0)20 3727 1000 



 
Notes for Editors
 
About Oxford BioDynamics Plc
 
Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a biotechnology company focused on the discovery and development of epigenetic biomarkers, based on regulatory 3D genome architecture, for use within the pharmaceutical and biotechnology industry. 
 
The Company's award-winning, proprietary technology platform, EpiSwitch™, offers non-invasive liquid biopsy readouts to the standards of validated predictive, prognostic and diagnostic patient stratifications, and aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine. 
 
In particular, EpiSwitch™ offers non-invasive molecular read-outs with strong links to clinical outcomes, and helps reduce time to market, failure rates and the costs at every stage of drug discovery.  Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.
 
In April 2019, Oxford BioDynamics received the Queen's Award for Enterprise: Innovation. The Queen's Awards for Enterprise are the most prestigious awards for UK businesses.
 
The Company is headquartered in the UK and listed on the London Stock Exchange's AIM under the ticker "OBD".  For more information please visit www.oxfordbiodynamics.com.
 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
RAGUROORROUOUAR